EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates

Ying Yan, Qiao Li, Jianbin Li

Translational Breast Cancer Research · 2022-04 · 3 · 18-18

DOI: 10.21037/tbcr-21-45 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2022-04. Verfasst von Ying Yan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer …. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For HER2-positive breast cancer, with the widespread adoption of trastuzumab + pertuzumab as well as postoperative intensive treatments with antibody-drug conjugates (ADCs), such as trastuzumab emtansine (T-DM1), and tyrosine kinase inhibitors (TKIs), such as neratinib, in the (neo) adjuvant setting, it is difficult for the physicians to know what is the optimal strategy for the metastatic setting because of limited evidences from clinical trials. Trastuzumab deruxtecan (T-DXd), as a new generation of HER2-targeted ADC drugs, shows significant advantages in efficacy compared with the T-DM1 in patients previously treated with trastuzumab. How to make the strategies for stratification management of HER2-positive advanced breast cancer in the rising era of ADCs? How to evaluate the value of progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) as efficacy indicators in clinical trials for HER2-positive metastatic breast cancer? What is the prospect of T-DXd in first-line therapy? Our panel of authorities considers these problems in a round-table discussion.

Schlagwörter

Stichwörter der Autor:innen

HER2-positivemetastatic breast cancerpanel discussiontrastuzumab deruxtecan (T-DXd)

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China.

Zitieren

APA

Yan, Y., Li, Q., & Li, J. (2022). Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates. Translational Breast Cancer Research, 3, 18-18. https://doi.org/10.21037/tbcr-21-45

Vancouver

Yan Y, Li Q, Li J. Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates. Translational Breast Cancer Research. 2022;3:18-18. doi:10.21037/tbcr-21-45

BibTeX
@article{Yan2022,
  author = {Yan, Ying and Li, Qiao and Li, Jianbin},
  title = {Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates},
  journal = {Translational Breast Cancer Research},
  year = {2022},
  volume = {3},
  pages = {18--18},
  doi = {10.21037/tbcr-21-45}
}
Kostenlos starten →